Cell Cure Neurosciences Ltd.
POB 12247
Jerusalem
91121
Tel: 972-545-245-677
Fax: 972-2-642-9856
About Cell Cure Neurosciences Ltd.
Established in 2005, Cell Cure is located in Jerusalem, Israel on the campus of Hadassah Medical Center. Cell Cure’s mission is to become a leading supplier of human cell-based therapies for the treatment of retinal and neural degenerative diseases. Its technology platform is based on the manufacture of diverse cell products sourced from clinical-grade (GMP-compatible) human embryonic stem cells. Its current focus is the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. Cell Cure’s major shareholders include BioTime, Inc.(NYSE MKT and TASE: BTX), HBL Hadasit Bio-Holdings Ltd., and Teva Pharmaceuticals Industries Ltd.YEAR FOUNDED:
2005
LEADERSHIP:
CEO: Charles S. Irving
CSO: Benjamin Reubinoff
3 articles about Cell Cure Neurosciences Ltd.
-
BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
5/29/2018
BioTime, Inc., has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”).
-
Hadasit Bio-Holdings Ltd. And BioTime Complete Shares Swap Transaction In Cell Cure Neurosciences Ltd.
6/20/2017
-
BioTime and Subsidiary Cell Cure Neurosciences Ltd. Establish Innovative Cell Therapy Manufacturing Center in Israel
1/3/2017